-receiving cells. In particular, both inhibitors reduce CD30 shedding maintaining the anti-tumor effects of the ADC Brentuximab-Vedotin or the anti-CD30 Iratumumab on HL cells. Thus, spreading of ADAM10 activity due to ExoV can result in the release of cytokines, like TNFα, a lymphoma growth factor, or soluble molecules, like sMICA or sCD30, that potentially interfere with host immune surveillance
trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma.Condition or disease Intervention/treatment Phase Lymphoma Biological: iratumumab Phase 1 Phase 2 Detailed Description: OBJECTIVES: * Determine the safety and tolerability of MDX-060 monoclonal antibody in patients with refractory